Healthcare entity
All 1 tracked stories fall under one category: market-trends. Of the tracked stories, 1 of 1 also mention Arbutus Biopharma, the most common co-covered peer. Their average consequence score of 7 runs above the beat's 5.9 for that window. They are less corroborated than the beat average, carrying 2 original sources each against 2.5 for the same window.
Last mentioned: Aug 19, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: market-trends. Of the tracked stories, 1 of 1 also mention Arbutus Biopharma, the most common co-covered peer. Their average consequence score of 7 runs above the beat's 5.9 for that window. They are less corroborated than the beat average, carrying 2 original sources each against 2.5 for the same window. We currently track 1 Healthcare story that mention Genevant Sciences, all published on March 4, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 22 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Genevant Sciences. Shared-story counts are live from our verified record — not editorial picks.
Moderna has agreed to pay Roivant Sciences up to $2.25 billion to settle long-standing patent infringement claims regarding the Lipid Nanoparticle (LNP) technology used in its COVID-19 vaccine. The settlement provides a massive capital windfall for Roivant and Arbutus Biopharma while removing a major legal risk for Moderna.
Genevant Sciences is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
